Low-Dose Antipsychotics for Relapse Prevention

ثبت نشده
چکیده

A recall has been issued by Ortho-McNeil-Janssen Pharmaceuticals for specific lots of 3-mg Risperdal (risperidone) tablets and 2-mg generic risperidone tablets because of an uncharacteristic musty odor thought to come from trace amounts of 2,4,6-tribromoanisole (TBA), the metabolite of a chemical fungicide used to treat wooden pallets on which the products are stored.1 McNeil Consumer Health has also recalled one lot of over-the-counter Tylenol Extra Strength caplets (225 count) for the same musty odor.2 TBA is not believed to be toxic, but it has been associated with transient GI symptoms. Several months ago, a similar recall was issued by OrthoMcNeil Neurologics for specific lots of topiramate (Topamax).3 1FDA MedWatch Alert: Risperdal (risperidone) and risperidone: recall – uncharacteristic odor. Available at www.fda.gov/Safety/MedWatch. 2FDA MedWatch Alert: Tylenol extra strength caplets, 225 count bottles: recall – uncharacteristic odor. Available at www.fda.gov/Safety/MedWatch. 3FDA MedWatch Alert: Topamax (topiramate): recall – musty odor. Available at www.fda.gov/Safety/MedWatch. See Psychiatry Drug Alerts 2011;25 (April):25.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

BACKGROUND It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. AIM To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. DATA SOURCE Double-blind, ra...

متن کامل

Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

OBJECTIVE Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention....

متن کامل

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

OBJECTIVE The authors performed a systematic review and meta-analysis of studies of the potential of new-generation antipsychotic drugs to improve adherence and decrease relapse rates in patients with schizophrenia. METHOD Randomized, controlled trials comparing new-generation antipsychotic drugs with placebo and/or conventional antipsychotics were identified. Data on relapse, general treatme...

متن کامل

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials

BACKGROUND This meta-analysis of randomized controlled trials aimed to examine the advantages of long-acting injectable antipsychotics over placebo or oral medications regarding efficacy and safety for patients with bipolar disorder. METHODS Two categorical meta-analyses of randomized controlled trials were performed to compare study-defined relapse rate (primary), discontinuation rates, and ...

متن کامل

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons

Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse is highly associated with partial medication adherence or nonadherence in patients with first-ep...

متن کامل

Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study.

The expected therapeutic effect of estrogen as an adjunct treatment to antipsychotics in women suffering from schizophrenia for relapse prevention was to be tested under real-life conditions. A multicenter, randomized, placebo-controlled, double-blind, cross-over study based on an A-B-A-B (and/or B-A-B-A) design was applied. Forty-six hypoestrogenic women with schizophrenia hospitalized for the...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011